Measuring Insulin-like Growth Factor Binding Proteins in Melanoma Patients
Author Information
Author(s): Yu Jessie Z, Warycha Melanie A, Christos Paul J, Darvishian Farbod, Yee Herman, Kaminio Hideko, Berman Russell S, Shapiro Richard L, Buckley Michael T, Liebes Leonard F, Pavlick Anna C, Polsky David, Brooks Peter C, Osman Iman
Primary Institution: New York University School of Medicine
Hypothesis
Can measuring IGFBP-3 and -4 levels in melanoma patients provide clinical utility?
Conclusion
Decreased IGFBP-4 tumor expression might indicate progression from primary to metastatic melanoma, but measuring IGFBP-3 and -4 in sera does not have clinical utility.
Supporting Evidence
- Median IGFBP-4 tumor expression was significantly greater in primary versus metastatic patients (70% vs. 10%).
- A trend for greater median IGFBP-3 sera concentration was observed in metastatic versus primary patients (4.9 μg/ml vs. 3.4 μg/ml).
- Neither IGFBP-3 nor -4 correlated with survival in this subset of patients.
Takeaway
This study looked at two proteins in melanoma patients to see if they could help doctors understand the disease better, but they found that measuring these proteins in blood isn't helpful.
Methodology
The study involved 132 melanoma patients, measuring IGFBP-3 and -4 levels in tissues and sera using immunohistochemistry and ELISA assays.
Limitations
The study did not find significant correlations between IGFBP levels and survival, and the clinical utility of these measurements was not supported.
Participant Demographics
132 melanoma patients (64 male, 68 female; median age 56).
Statistical Information
P-Value
p = 0.01 for IGFBP-4 expression comparison.
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website